title: New approaches in hormone refractory prostate cancer.
abstract: Effective therapeutic options have not existed for prostate cancer progressing after androgen deprivation therapy until very recently. Docetaxel based chemotherapy has been demonstrated to extend survival in 2 large randomized trials. These studies have provided the impetus to combine docetaxel with novel biologic agents to further consolidate the gains in long-term outcome. With the arrival of exciting agents including vaccines, monoclonal antibodies, bone-targeted drugs, antisense oligonucleotides, antiangiogenic drugs, and small molecule receptor tyrosine kinase inhibitors, the future of prostate cancer therapy appears promising.
authors.affiliation: U.S. Oncology Research Network, Houston, TX, USA. guru.sonpavde@usoncology.com
authors.forename: Guru
authors.initials: G
authors.lastname: Sonpavde
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Hutson
mesh_terms: D000726:Androgen Antagonists / Q000494:pharmacology*; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D019496:Cancer Vaccines; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006131:Growth Inhibitors / Q000627:therapeutic use; D006801:Humans; D008297:Male; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D061988:Proteasome Inhibitors; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D000726:Androgen Antagonists; D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000972:Antineoplastic Agents, Phytogenic; D019496:Cancer Vaccines; D004791:Enzyme Inhibitors; D006131:Growth Inhibitors; D016376:Oligonucleotides, Antisense; D061988:Proteasome Inhibitors; D043823:Taxoids; D000077143:Docetaxel